⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NAGE News
Niagen Bioscience, Inc. Common Stock
Form 8-K
sec.gov
NAGE
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
prnewswire.com
NAGE
OCGN
NTLA
GERN
Form 8-K
sec.gov
NAGE
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
businesswire.com
NAGE
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen ®
businesswire.com
NAGE
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen
businesswire.com
NAGE
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
businesswire.com
NAGE
Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science
globenewswire.com
CGC
NAGE
SBEV
ZVIA
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
globenewswire.com
LEXX
WST
NAGE
PM
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen ®, the Leading NAD+ Supplement in the U.S.*
businesswire.com
NAGE